• Sonuç bulunamadı

SİNAN BEKSAÇ

N/A
N/A
Protected

Academic year: 2021

Share "SİNAN BEKSAÇ"

Copied!
16
0
0

Yükleniyor.... (view fulltext now)

Tam metin

(1)

Down sendromlu bebek

taşıyan gebelerin metabolik altyapıları; Metabolomiksler

Prof. Dr. M. Sinan Beksaç, Perinatoloji Bilim Dalı Başkanı Hacettepe Üniversitesi Tıp Fakültesi

31 Mayıs/01 Haziran 2018, ANKARA

Türkiye Maternal-Fetal Tıp ve Perinatoloji Derneği, Fetal Tıp Subgrup Toplantısı

(2)

Sunumun Konusu

Metabolizmadaki değişiklikler ve ilişkili epigenetik fatörlerin, gametogenesis sırasında 1. ve 2. mayoz dönemlerinde aberran rekombinasyona sebeb olup olamıyacağı → Down sendromu !!!

Yani, söz konusu metabolik farklılığın gametogenezis ve embryogenesis

üzerinden Down sendrom’lu fetusların oluşumunda rol alıp alamayacağı !!!

(3)

Metabolomikler

3000 Da altındaki moleküler yapılar; Polar ve yağda çözünür, asidik veya bazik, stabil veya labil olabilirler

Değişik enzim yolaklarının ürünleridir

(4)

Metabolomik Analiz

METABOLITES

Polar & Lipid soluble Acidic & basic

Stable & highly unstable

ANALYTICAL METHODS

NMR

MS (GC/LC, DI)

FT-IR

(5)

Çalışmamızın Kurgusu

21 Down sendromlu fetus taşıyan gebe 32 Normal gebelik

ve metabolitlerin GC-MS ve LC-qTOF-MS ile

çalışılması

(6)

Metabolomik Analiz

gaz kromatografisi-kitle spektrometresi (GC-MS):

95 metabolit

sıvı kromatografisi-kitle spektrometresi (LC-qTOF-MS):

301 metabolit

(7)

-7 -6 -5 -4 -3 -2 -1 0 1 2 3 4 5 6 7

-11 -10 -9 -8 -7 -6 -5 -4 -3 -2 -1 0 1 2 3 4 5 6 7 8 9 10 11

t[2]

t[1]

R2X[1] = 0.151271 R2X[2] = 0.100157 Ellipse: Hotelling T2 (0.95)

Kontrol Trizomi 21

AYTU

BUCA CEER

DIAL EYUL

FAKI FASU FETI

GUER GUOZ

HAAL HADA

HAEM HAKO

ILKA

MIAR MUKU

NUCA

RERA

RUKU SA_B

SIOK SOSA

SUSA VIKO

YAAY ZEAK ZEKA

ZOBA ZUEK

AYCA

AYUN BEAT

BEOZ FAUN KSKN

NEON

OZAY OZNE

PISI RUBA

SEDU SEKA

SEUN SIKO TUAL

TUCA YALI

ZUDE

SIMCA-P+ 12.0. 1 - 2015-08-13 17:23:52 (UTC-6)

2-hydroxybutyric acid Beta alanine Benzoic acid Threonic acid Nonanoic acid Oxalic acid alpha Tocopherol Uracil 2-piperidone 3-HBA 2-ketoisocaproic acid 4-isopropylbenzoic acid Cholestorol Pyruvic acid Creatinine

0.0 0.5 1.0 1.5 2.0 2.5

VIP

-0.2 -0.1 0.0 0.1 0.2

2-hydroxybutyric acid Benzoic acid Nonanoic acid 3-HBA 2-ketoisocaproic acid 4-isopropylbenzoic acid 2-piperidone Oxalic acid Uracil Cholestorol Pyruvic acid alpha Tocopherol Creatinine Beta alanine Threonic acid

Coefficient

C

PLS-DA Down

Syndrome Control

Discrimination of metabolomic profiles

B

D e cr e as e d in D o w n sy n d ro m e

In cr e as e d in D o w n sy n d ro m e

A

GC-MS

(8)

GC-MS Sonuçları

«Down» grubunda artan metabolitler: Önem sırasına göre

2-hydroxybutyric acid,

benzoic acid,

nonanoic acid ,

3-hydroxybutyric acid

2-ketoisocaproic acid

(9)

GC-MS Sonuçları

«Down» grubunda azalan metabolitler: Önem sırasına göre

beta-alanine

threonic acid

oxalic acid

creatinine

alpha tocopherol

uracil

2-piperidone

(10)

PI(O-18:0/14:0) PI(16:0/22:4(10Z,13Z,16Z,19Z)) PC 1 GL 1 LysoPC(20:4(5Z,8Z,11Z,14Z)) PC 2 9-methoxy-pentadecanoic acid PE(18:1(11Z)/P-18:1(11Z)) Creatine N4-Phosphoagmatine N6-Acetyl-N6-hydroxy-L-lysine LysoPC(20:3(5Z,8Z,11Z)) PE 1 Citrate PI(16:0/22:5(4Z,7Z,10Z,13Z,16Z)) 5'-Phosphoribosylglycinamide PI(16:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)) PS 1 PE 3 2,5-Dioxopentanoate PG(O-18:0/15:0) PE 4 PI(13:0/22:2(13Z,16Z)) Pyruvate Tetrahomomethionine D-Fructose 2-Furoate 1-Linoleoylglycerophosphocholine PG(O-18:0/17:0) PE 2 0.0

0.5 1.0 1.5 2.0 2.5

VIP

-0.04 -0.02 0.00 0.02 0.04 PS 1

Creatine N4-Phosphoagmatine Citrate 2,5-Dioxopentanoate 2-Furoate PG(O-18:0/17:0) Pyruvate GL 1 D-Fructose PE 4 PE 2 PE 3 PE 1 1-Linoleoylglycerophosphocholine PE(18:1(11Z)/P-18:1(11Z)) LysoPC(20:4(5Z,8Z,11Z,14Z)) LysoPC(20:3(5Z,8Z,11Z)) PI(16:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)) PI(16:0/22:5(4Z,7Z,10Z,13Z,16Z)) Tetrahomomethionine PG(O-18:0/15:0) PI(13:0/22:2(13Z,16Z)) PC 2 N6-Acetyl-N6-hydroxy-L-lysine 5'-Phosphoribosylglycinamide 9-methoxy-pentadecanoic acid PI(16:0/22:4(10Z,13Z,16Z,19Z)) PI(O-18:0/14:0) PC 1

Coefficient

C

PLS-DA

Down Syndrome Control

Metabolomic profile

B A

LC-qTOF-MS

D e cr e as e d in D o w n sy n d ro m e

In cr e as e d in D o w n sy n d ro m e

(11)

LC-qTOF-MS Sonuçları

«Down» grubunda artan Metabolitler: Önem sırasına göre

Creatine

N4-Phosphoagmatine

citrate

2,5-dioxopentanoate

2-furoate

pyruvate

fructose

(12)

LC-qTOF-MSSonuçları

«Down» grubunda azalan Metabolitler:

lipid ilişkili metabolitler

(13)

Sonuç’ta Etkilenen Metabolik yolaklar

aminoacyl-tRNA biosynthesis

“glycine-serine-threonine” metabolism

nitrogen metabolism

“alanine-aspartate-glutamate” metabolism

propanoate metabolism

“valine-leucine-isoleucine” biosynthesis

glycerophospholipid metabolism

metabolism of cysteine and methionine

phenylalanine metabolism

(14)

Bir çeşit Metabolik Sendrom!!!:

1. Oksidatif stres,

2. Etkilenmiş aminoasit-lipid metabolizması 3. Değişen enerji metabolizması

4. Etkilenen DNA Metilasyon yolağı 4. DNA-RNA iletişim problemi

5. Hücre zarı instabilitesi

(15)

Patolojik Maternal Metabolizma ve Down sendromu varlığı !! ?

Ovulasyon sırasında, 1. ve 2. mayotik bölünme hataları

Erken gebelik döneminde «embriyogenezis ve

organogenezis problemleri

(16)

DOWN

SYNDROME

1 Emirhan Nemutlu, 2 Gokcen Orgul, 1 Tuba Recber, 2 Emine Aydın, 3 Mehmet Alikaşifoğlu, 1 Sedef Kır, and 2 M. Sinan Beksac

1 Department of Analytical Chemistry, Faculty of Pharmacy, 2 Division of Perinatology, Department of

Obstetrics and Gynecology and 3 Department of Genetics, Medical Faculty, Hacettepe University,

Ankara, Turkey

Referanslar

Benzer Belgeler

Properties: White or whitish, crystalline powder or colorless crystals, colorless when in contact with air and moisture-absorbing. Solubility: Easily soluble in water, soluble

 Using a cyclic anhydride allows for only one of the acid groups to react, leaving the second acid group free to undergo further reactions... Acetic

The signal transduction pathway of lipoteichoic acid (LTA)-induced increase of cyclooxygenase (COX) activity and COX-2 expression was studied in human pulmonary epithelial cell

method of flowcytometry, (5) use of rat primary hepatocyte as the model for de tecting antioxidant activity against oxidative stress.In the results, HA and β-PPA showed

Bonviva R (Ibandronic acid) - 骨維壯 注射劑 [ 發表藥師 ] :陳怡潔 藥師. [ 發布日期

Bonviva R (Ibandronic acid) - 骨維壯 注射劑 [ 發表藥師 ] :陳怡潔 藥師. [ 發布日期

由此可知, 口服投予 methyl caffeate 及 ethyl caffeate 並無法增加 caffeic acid 之生成, 而以靜脈投予, ethyl caffeate 水解生成 caffeic acid 比例比 methyl

which is predicted from the intravenous pharmacokinetic parameters nearly made the rabbits'' plasma to reach the steady-state